BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A

European Commission Approval Expected Q3 2022 1st Gene Therapy for Treatment of Hemophilia A Recommended for Approval in Europe More than 20,000 Adults with Severe Hemophilia A in BioMarin Territories Across Europe, the Middle East and Africa Conf... Biopharmaceuticals, Regulatory BioMarin Pharmaceutical, Valoctocogene Roxaparvovec, Hemophilia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news